PMID- 36845696
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230228
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally 
      advanced esophageal squamous cancer.
PG  - 1005856
LID - 10.3389/fonc.2023.1005856 [doi]
LID - 1005856
AB  - OBJECTIVE: To compare effects and adverse events of anti-programmed cell death 
      protein 1 (anti-PD-1) antibody combined with chemoradiotherapy (CRT) and CRT 
      alone as the initial treatment in locally advanced esophageal squamous cell 
      carcinoma (ESCC). METHODS: We retrospectively reviewed locally advanced ESCC 
      patients who received Anti-PD-1+CRT as initial treatment at 3 institutions. 
      Primary outcomes of interest were progression-free survival (PFS) and overall 
      survival (OS); secondary outcomes were objective response rate (ORR), disease 
      control rate (DCR), duration of response (DoR), and treatment-related adverse 
      events (AEs) including immune-related adverse events (irAEs). RESULTS: At data 
      cutoff, 81 patients were included (30 Anti-PD-1+CRT, 51 CRT). Median follow-up 
      was 31.4 months. Anti-PD-1+CRT resulted in significant improvements in PFS 
      (median, 18.6 vs. 11.8 months, HR 0.48 [95% CI, 0.29-0.80], P = 0.008), and OS 
      (median, 27.7 vs. 17.4 months, HR 0.37 [95% CI, 0.22-0.63], P = 0.002), compared 
      with CRT in ESCC. The ORR and DCR of patients treated with Anti-PD-1+CRT were 
      also significantly higher than those treated with CRT (80.0% vs. 56.9%, P = 
      0.034), (100% vs. 82.4%, P = 0.023), respectively. Anti-PD-1+CRT had better 
      durable response compared with CRT, with DoR (median,17.3 vs. 11.1 months, P = 
      0.022). Treatment-related adverse event incidence was similar between the two 
      groups (any Grade, 93.3% vs. 92.2%; >/=Grade 3, 50.0% vs. 33.3%). CONCLUSION: 
      Anti-PD-1 plus chemoradiotherapy demonstrated promising antitumor activity and 
      was well tolerated in locally advanced ESCC.
CI  - Copyright (c) 2023 Ma, Yao, Lu, Qu, Cui, Yuan, Li, Tong, Qin and Yao.
FAU - Ma, Ji
AU  - Ma J
AD  - Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu, China.
FAU - Yao, Nan
AU  - Yao N
AD  - Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu, China.
FAU - Lu, Jiaying
AU  - Lu J
AD  - Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu, China.
FAU - Qu, Wanxi
AU  - Qu W
AD  - Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu, China.
FAU - Cui, Li
AU  - Cui L
AD  - Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu, China.
FAU - Yuan, Shiwang
AU  - Yuan S
AD  - Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu, China.
FAU - Li, Na
AU  - Li N
AD  - Department of Radiation Oncology, Xuzhou Central Hospital, Xuzhou, Jiangsu, 
      China.
FAU - Tong, Shaodong
AU  - Tong S
AD  - Department of Radiation Oncology, The Third People's Hospital of Xuzhou, Xuzhou, 
      Jiangsu, China.
FAU - Qin, Zhaohui
AU  - Qin Z
AD  - Research Center for Medical and Health Emergency Rescue, Xuzhou Medical 
      University, Xuzhou, Jiangsu, China.
FAU - Yao, Yuanhu
AU  - Yao Y
AD  - Department of Radiation Oncology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu, China.
AD  - School of Medical Imaging, Xuzhou Medical University, Xuzhou, Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20230209
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9947779
OTO - NOTNLM
OT  - anti-PD-1 antibodies
OT  - chemoradiotherapy
OT  - esophageal squamous cell carcinoma
OT  - overall survival (OS)
OT  - progression-free survival (PFS)
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/02/28 06:00
MHDA- 2023/02/28 06:01
PMCR- 2023/01/01
CRDT- 2023/02/27 05:19
PHST- 2022/09/01 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/02/27 05:19 [entrez]
PHST- 2023/02/28 06:00 [pubmed]
PHST- 2023/02/28 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1005856 [doi]
PST - epublish
SO  - Front Oncol. 2023 Feb 9;13:1005856. doi: 10.3389/fonc.2023.1005856. eCollection 
      2023.